



**Department
of Health**

People Living With

HIV/AIDS

Value Based Payment Quality Measure Set
Measurement Year 2024



INTRODUCTION

The Measurement Year (MY) 2024 People Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) Quality Measure Set was created in collaboration with the People Living with HIV/AIDS Quality of Care Clinical Advisory Committee (QAC), the Primary Care (Physical Health), and the Behavioral Health/Health and Recovery Plan (HARP) Clinical Advisory Groups (CAGs), as well as the New York State Department of Health (NYS DOH) CAG Strategy team. The goal of this measure set is to align with measures put forth in the NYS Quality Assurance Reporting Requirements (QARR), the Healthcare Effectiveness Data and Information Set® (HEDIS)¹ Technical Specifications for Health Plans, the Centers for Medicare & Medicaid Services (CMS) Core measure set, and the Merit-based Incentive Payment System (MIPS), where applicable. The measure set is designed to encourage providers to meet high standards of patient-centered clinical care and coordination across multiple care settings.

MEASURE SELECTION AND FEASIBILITY

Upon receiving recommendations from the QAC & CAGs, the release of guidelines from national measure stewards, such as the National Committee for Quality Assurance (NCQA)/HEDIS and CMS, and in accordance with the NYS Value Based Payment (VBP) Roadmap² the State defined a final list of measures to be included in the HIV/AIDS Measure Set for MY2024. For MY2024 there are a total of thirty-one Category 1 and 2 People Living with HIV/AIDS Quality Measures.

VBP ARRANGEMENT REQUIREMENTS FOR MY2024 – HEALTH EQUITY

In MY2022, NCQA added race and ethnicity (RAE) stratification for five HEDIS measures to help promote transparency in health plan performance; another eight were added for MY2023. By doing so, NCQA hopes to better identify where disparities exist so they can be addressed. They also hope to identify and learn from top performers in areas where disparities don't exist. To align with this initiative, starting in July 2022, NYS has required payers and providers to incorporate race and ethnicity measure stratification in Value Based Payment (VBP) arrangements. For MY2024, HEDIS added nine additional measures for race and ethnicity stratification, totaling 22 measures spanning numerous domains and VBP arrangement types.

Stratification Specifications:

1. Payers are **required** to include **at least one** of the following measures in **all level 1 or higher** VBP contracts and stratify results by race and ethnicity categories as outlined in the HEDIS MY2024 specifications.³

NCQA Measure Name	Measure Inclusion by Arrangement Type				
	TCGP	HARP/BH	Maternity	HIV/AIDS	Children's
Adult Immunization Status (AIS-E)	✓				
Asthma Medication Ratio (AMR)	✓	✓		✓	✓
Breast Cancer Screening (BCS-E)	✓	✓		✓	
Cervical Cancer Screening (CCS; CCS-E)*	✓	✓		✓	
Child and Adolescent Well-Care Visits (WCV)	✓				✓
Childhood Immunization Status (CIS; CIS-E)*	✓				✓

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

² New York State Department of Health, Medicaid Redesign Team, A Path Toward Value-Based Payment: Annual Update, September 2019. [\(Link\)](#)

³ HEDIS® Measurement Year 2024 Volume 2 Technical Specification for Health Plans, General Guidelines section, page 28



NCQA Measure Name	Measure Inclusion by Arrangement Type				
	TCGP	HARP/BH	Maternity	HIV/AIDS	Children's
Colorectal Cancer Screening (COL-E)	✓	✓		✓	
Controlling High Blood Pressure (CBP)	✓	✓		✓	
Eye Exam for Patients with Diabetes (EED)*	✓	✓		✓	
Follow-Up After Emergency Department Visit for Mental Illness (FUM)*	✓	✓			✓
Follow-Up After Emergency Department Visit for Substance Use (FUA)	✓	✓			
Follow-Up After Hospitalization for Mental Illness (FUH)*	✓	✓			
Glycemic Status Assessment for Patients with Diabetes (GSD) (Formerly Hemoglobin A1c – HBD)	✓	✓		✓	
Immunizations for Adolescents – Combo 2 (IMA, IMA-E)	✓				✓
Initiation and Engagement of Substance Use Disorder Treatment (IET)	✓		✓	✓	
Kidney Health Evaluation for Patients with Diabetes (KED)*	✓	✓		✓	
Pharmacotherapy for Opioid Use Disorder (POD)	✓	✓			
Postpartum Depression Screening and Follow-Up(PDS-E)*			✓		
Prenatal and Postpartum Care (PPC)	✓		✓		
Prenatal Depression Screening and Follow-Up (PND-E)*			✓		
Prenatal Immunization Status (PRS-E)*	✓		✓		
Well-Child Visits in the First 30 Months of Life (W30)	✓				✓

* Added for MY2024

Stratification Requirements:

1. Stratification of selected measures is to be classified as pay-for-reporting (P4R).
2. Payers are **required** to include the following details in the Provider Contract Statement and Certification form (DOH-4255) and Contract language:
 - i. Indicate what measure(s) are included for race and ethnicity stratification.
 - ii. Indicate how the stratified measure results for applicable measures will be shared with the VBP contractor.
3. Plans are required to include the race and ethnicity data to NYS using the following method:
 - i. Race and ethnicity fields have been added to the annual VBP member attribution submission file specifications. This will allow the State to stratify measure performance by race and ethnicity categories for applicable performance measures at the VBP contract and VBP Contractor levels.

All new contracts submitted on or after July 1, 2022, must meet this requirement to be approved by NYS DOH. As of April 1, 2023, all other existing contracts were to be updated/amended at the end of the contract's current measurement period and before the contract's next measurement period began.

MEASURE CLASSIFICATION

Each measure has been designated by the State as a Category 1, 2, or 3 with associated recommendations for implementation and testing for future use in VBP Arrangements. The measures below are classified by category based on an assessment of reliability, validity, and feasibility, and according to the suggested method of use (either Pay for Reporting (P4R) or Pay for Performance (P4P)).

Category 1

Category 1 quality measures, as identified by the CAGs and accepted and deemed reportable by the State, are to be reported by VBP Contractors to the Managed Care Organizations (MCOs). These measures are intended to be used to determine the amount of shared savings for which VBP contractors are eligible.⁴ At least one Category 1 P4P measure must be included in a VBP contract.

The State classifies each Category 1 measure as either P4P or P4R:

- **P4P** measures are intended to be used in the determination of shared savings amounts for which VBP Contractors are eligible. In other words, these are the measures on which payments in VBP contracts may be based. Measure performance can be considered in both the determination of the target budget and in the calculation of shared savings for VBP Contractors.
- **P4R** measures are intended to be used by the MCOs to incentivize VBP Contractors to report data to monitor the quality of care delivered to members under a VBP contract. Incentives for reporting should be based on timeliness, accuracy, and completeness of data. Measures can be reclassified from P4R to P4P or vice versa through annual CAG and State review or as determined by the MCO and VBP Contractor.

Not all Category 1 measures will be reportable for the measurement year, as reporting on some of these measures will be phased in over the next few years. Please refer to the *2024 Value Based Payment Reporting Requirements Technical Specifications Manual (MY2024)* for details as to which measures must be reported for the measurement year. This manual will be updated annually, in line with the release of the final VBP measure sets for the subsequent year.

Categories 2 and 3

Category 2 measures have been accepted by the State based on the agreement of clinical importance, validity, and reliability but flagged as presenting concerns regarding implementation feasibility. The State has discussed measure testing approaches, data collection, and reporting requirements with VBP CAGs.

Measures designated as Category 3 were identified as unfeasible at this time or as presenting additional concerns, including accuracy or reliability when applied to the attributed member population for an arrangement; therefore, Category 3 measures are not included in the measure set.

Categorizing and Prioritizing Quality Measures

	CATEGORY 1 Approved quality measures that are deemed to be clinically relevant, valid, and feasible.
	CATEGORY 2 Measures that are clinically relevant, valid, and reliable, but where the feasibility could be problematic.
	CATEGORY 3 Measures that are insufficiently relevant, valid, reliable and/or feasible.

⁴ New York State Department of Health, Medicaid Redesign Team, Value Based Payment: Update, May 2022. [\(Link\)](#)



MY2024 HIV/AIDS QUALITY MEASURE SET

The measures provided on the following pages are recommendations for MY2024. Note that measure classification is a NYS recommendation, and implementation is to be determined between the MCO and VBP Contractor.

Measure sets and classifications are considered dynamic and will be reviewed annually. Updates will include measure additions, deletions, steward changes, recategorizations, and/or reclassifications from P4R to P4P or vice versa, based on experience with measure implementation in the prior year. Please see [Appendix A](#) for a full list of these changes.

CATEGORY 1

The table below displays the **Category 1 HIV/AIDS Quality Measure Set**, arranged alphabetically and includes the measure title, measure steward, and State-recommended classification for measure use. The measure set is redlined to highlight changes made between MY2023 and MY2024; please refer to the key at the end of this table for an explanation of redlined formatting.

HIV/AIDS Measures	Measure Steward	Classification
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder	Centers for Medicare & Medicaid Services (CMS)	P4P
Antidepressant Medication Management – Effective Acute Phase Treatment & Effective Continuation Phase Treatment (AMM)*	National Committee for Quality Assurance (NCQA)	P4P
Asthma Medication Ratio (AMR)	NCQA	P4P
Breast Cancer Screening (BSC-E)^	NCQA	P4P
Cervical Cancer Screening (CCS; CCS-E)^	NCQA	P4P
Colorectal Cancer Screening (COL; COL-E)^	NCQA	P4P
Controlling High Blood Pressure (CBP)	NCQA	P4P
COVID-19 Immunization Measure (CVS)^	NYS	P4P
Depression Remission or Response for Adolescents and Adults (DRR-E)	NCQA	P4P
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)	NCQA	P4R
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	NCQA	P4P



HIV/AIDS Measures	Measure Steward	Classification
Eye Exam for Patients with Diabetes (EED)^	NCQA	P4P
Hemoglobin A1c Control for Patients with Diabetes (HBD) Glycemic Status Assessment for Patients with Diabetes (GSD)^	NCQA	P4P
HIV Viral Load Suppression (HVL-AD)	Health Resources and Services Adm (HRSA)	P4P
Initiation and Engagement of Substance Use Disorder Treatment (IET)	NCQA	P4P
Initiation of Pharmacotherapy upon New Episode of Opioid Dependence (POD-N)	NYS	P4P
Kidney Health Evaluation for Patients with Diabetes (KED)^	NCQA	P4P
Potentially Avoidable Complications in Patients with HIV/AIDS	Altarum Institute	P4R
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	CMS	P4R
Preventive Care and Screening: Influenza Immunization	NCQA	P4R
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention^	NCQA	P4R
Sexually Transmitted Infections: Screening for Chlamydia, Gonorrhea, and Syphilis	NYS	P4R
Social Need Screening and Intervention (SNS-E)^	NCQA	P4R P4P
Statin Therapy for Patients with Cardiovascular Disease (SPC)^	NCQA	P4R P4P
Use of Pharmacotherapy for Alcohol Abuse or Dependence	NYS	P4R
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	NCQA	P4R

*To Be Retired MY2025-MY2026

Retired/Removed for MY2024

^Measure Revised for MY2024



CATEGORY 2

The table below displays the Category 2 People Living with HIV/AIDS Quality Measure Set and includes the measure title, measure steward, and the NQF number (where applicable). All Category 2 measures are classified as P4R in MY2024. Category 2 measures were reviewed in detail this year and streamlined to include only those with an active measure steward and/or potential for movement to Category 1 in subsequent years. The measure set is redlined to highlight changes made between MY2023 and MY2024; please refer to the key at the end of this table for an explanation of redlined formatting.

HIV/AIDS Measures	Measure Steward
Asthma Action Plan	American Academy of Allergy, Asthma & Immunology (AAAAI)
Asthma: Assessment of Asthma Control – Ambulatory Care Setting	AAAAI
Asthma: Spirometry Evaluation	AAAAI
Continuing Engagement in Treatment (CET) Alcohol and Other Drug Dependence	NYS
Continuity of Care from Inpatient Detox to Lower Level of Care	NYS
Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)*	University of Southern California (USC)
Diabetes Screening	NYS
Hepatitis C Screening	HRSA
Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver (asthma)	The Joint Commission (TJC)
Housing Status	HRSA
Linkage to HIV Medical Care	NYS
Pharmacotherapy for Opioid Use Disorder (POD)	NCQA
Prescription of HIV Antiretroviral Therapy	HRSA
Sexual History Taking: Anal, Oral, and Genital (HIV/AIDS)	NYS
Substance Abuse Screening	HRSA

*New Measure MY2024

~~Retired/Removed for MY2024~~



Appendix A



The table below identifies the changes to the Category 1 and Category 2 measures for the MY2024 HIV/AIDS Quality Measure Set.

CATEGORY 1 & 2 MEASURE CHANGES FROM 2023 TO 2024

Category 1 Measure Changes from 2023 to 2024

Measure Name	Change	Rationale for Change
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder	Measure removed	Steward no longer supports measure.
Antidepressant Medication Management – Effective Acute Phase Treatment & Effective Continuation Phase Treatment (AMM)	Proposed Retirement	To be retired by NCQA in MY2025
Breast Cancer Screening (BCS-E)	Measure reporting specifications revised by NCQA for HEDIS MY2024	Implemented gender-inclusive language
Cervical Cancer Screening (CCS; CCS-E)	Measure reporting specifications revised by NCQA for HEDIS MY2024	Implemented gender-inclusive language
Cervical Cancer Screening (CCS; CCS-E)	HEDIS Stratified Measure	Added to NCQA list of Race and Ethnicity measures – New for MY2024
Colorectal Cancer Screening (COL; COL-E)	Measure reporting specifications revised by NCQA for HEDIS MY2024	ECDS Reporting only
COVID-19 Immunization Measure (CVS)	Measure reporting specifications revised by NYS for MY2024	Refer to Quality Assurance Reporting Requirements (QARR) Technical Specifications for MY2024.
Eye Exam for Patients with Diabetes (EED)	Measure reporting specifications revised by NCQA for HEDIS MY2024	Revised diabetes denominator
Eye Exam for Patients with Diabetes (EED)	HEDIS Stratified Measure	Added to NCQA list of Race and Ethnicity measures – New for MY2024
Hemoglobin A1c Control for Patients with Diabetes (HBD)	Name and specifications revised for MY2024, now: Glycemic Status Assessment for Patients with Diabetes (GSD)	Revised diabetes denominator; Inclusion of Glucose Management Indicator (GMI)
Kidney Health Evaluation for Patients with Diabetes (KED)	HEDIS Stratified Measure	Added to NCQA list of Race and Ethnicity measures – New for MY2024



Measure Name	Change	Rationale for Change
Potentially Avoidable Complication (PAC) in Patients with HIV/AIDS	Measure removed from HIV/AIDS MY2024 CAT 1 measure set	Steward no longer supports measure.
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Measure reporting specifications revised by CMS for MY2024	Revised age group of the initial population.
Social Need Screening and Intervention (SNS-E)	Classification change	Second year measure; changed to P4P.
Statin Therapy for Patients with Cardiovascular Disease (SPC)^	Classification change	Second year measure; changed to P4P.
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	Measure removed	HEDIS/NCQA retired measure for MY2024

Category 2 Measure Changes from 2023 to 2024

Measure Name	Change	Rationale for Change
Asthma: Spirometry Evaluation	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	Steward no longer supports measure.
Continuity of Care from Inpatient Detox to Lower Level of Care	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	NYS no longer collects measure
Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)	New measure to HIV/AIDS MY2024 CAT 2 measure set	Replaced Pharmacotherapy for Opioid Use Disorder (POD) measure
Diabetes Screening	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	NYS no longer collects measure
Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver (asthma)	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	Steward no longer supports measure.
Linkage to HIV Medical Care	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	NYS no longer collects measure
Medical Case Management: Care Plan	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	NYS no longer collects measure
Pharmacotherapy for Opioid Use Disorder (POD)	Measure removed from HIV/AIDS MY2024 CAT 2 measure set	Replaced by Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)



**Department
of Health**

2024 VBP HIV/AIDS Quality Measure Set